Literature DB >> 17822678

DKC1 is a direct and conserved transcriptional target of c-MYC.

Faizan Alawi1, Megan N Lee.   

Abstract

Recent studies have identified upregulation of the dyskeratosis congenita 1 (DKC1) gene in association with various sporadic cancers. Whole genome analyses have suggested that DKC1 may be regulated by the c-MYC oncoprotein. c-MYC is among the most commonly deregulated proteins in human cancer. However, controversy remains as to whether DKC1 is a direct or indirect target of c-MYC. Using human and rodent cell lines expressing conditionally active c-MYC transgenes, we show that c-MYC activation is associated with relatively acute induction of DKC1 expression. Chromatin immunoprecipitation assays reveal c-MYC binding to two distinct, phylogenetically conserved regions within the DKC1 promoter and intron one. We further demonstrate that c-MYC-mediated Dkc1 transcription can occur in the absence of de novo protein synthesis. These data indicate that DKC1 is a direct and conserved transcriptional target of c-MYC, and suggest a biologic basis for DKC1 overexpression in neoplasia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17822678     DOI: 10.1016/j.bbrc.2007.08.071

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Correlation of dyskerin expression with active proliferation independent of telomerase.

Authors:  Faizan Alawi; Ping Lin; Barry Ziober; Reena Patel
Journal:  Head Neck       Date:  2010-12-08       Impact factor: 3.147

2.  Dyskerin is required for tumor cell growth through mechanisms that are independent of its role in telomerase and only partially related to its function in precursor rRNA processing.

Authors:  Faizan Alawi; Ping Lin
Journal:  Mol Carcinog       Date:  2010-12-10       Impact factor: 4.784

Review 3.  Ribosome biogenesis: emerging evidence for a central role in the regulation of skeletal muscle mass.

Authors:  Thomas Chaillou; Tyler J Kirby; John J McCarthy
Journal:  J Cell Physiol       Date:  2014-11       Impact factor: 6.384

4.  Differential requirements for H/ACA ribonucleoprotein components in cell proliferation and response to DNA damage.

Authors:  Ping Lin; Maral E Mobasher; Yasaman Hakakian; Veena Kakarla; Anum F Naseem; Heliya Ziai; Faizan Alawi
Journal:  Histochem Cell Biol       Date:  2015-08-12       Impact factor: 4.304

5.  MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Authors:  Javier A Baena-Del Valle; Qizhi Zheng; David M Esopi; Michael Rubenstein; Gretchen K Hubbard; Maria C Moncaliano; Andrew Hruszkewycz; Ajay Vaghasia; Srinivasan Yegnasubramanian; Sarah J Wheelan; Alan K Meeker; Christopher M Heaphy; Mindy K Graham; Angelo M De Marzo
Journal:  J Pathol       Date:  2017-11-14       Impact factor: 7.996

6.  Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion.

Authors:  Fa-An Miao; Kun Chu; Hai-Rong Chen; Meng Zhang; Pei-Cong Shi; Jin Bai; Yong-Ping You
Journal:  Invest New Drugs       Date:  2019-03-07       Impact factor: 3.850

Review 7.  Non-canonical roles of canonical telomere binding proteins in cancers.

Authors:  Semih Can Akincilar; Claire Hian Tzer Chan; Qin Feng Ng; Kerem Fidan; Vinay Tergaonkar
Journal:  Cell Mol Life Sci       Date:  2021-02-18       Impact factor: 9.261

8.  Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer.

Authors:  Stefan J Barfeld; Ladan Fazli; Margareta Persson; Lisette Marjavaara; Alfonso Urbanucci; Kirsi M Kaukoniemi; Paul S Rennie; Yvonne Ceder; Andrei Chabes; Tapio Visakorpi; Ian G Mills
Journal:  Oncotarget       Date:  2015-05-20

9.  DKC1 overexpression associated with prostate cancer progression.

Authors:  P Sieron; C Hader; J Hatina; R Engers; A Wlazlinski; M Müller; W A Schulz
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

10.  Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis.

Authors:  Bei Liu; Jinglei Zhang; Chen Huang; Hui Liu
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.